S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

$55.50
+2.40 (+4.52%)
(As of 05:19 PM ET)
Compare
Today's Range
$52.43
▼
$55.52
50-Day Range
$50.00
▼
$61.26
52-Week Range
$6.93
▼
$63.40
Volume
298,189 shs
Average Volume
457,753 shs
Market Capitalization
$3.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.80
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

MoonLake Immunotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
5.9% Upside
$58.80 Price Target
Short Interest
Healthy
16.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$60.53 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.93) to ($1.22) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

825th out of 964 stocks

Pharmaceutical Preparations Industry

383rd out of 445 stocks

See Top Rated MarketRank™ Stocks Here

MLTX stock logo

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

MLTX Price History

MLTX Stock News Headlines

September 25, 2023 | americanbankingnews.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by Brokerages
September 19, 2023 | americanbankingnews.com
Cantor Fitzgerald Reiterates "Overweight" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 18, 2023 | finance.yahoo.com
These 8 Stocks Are Outperforming Nvidia In 2023
September 17, 2023 | msn.com
Acelyrin, MoonLake rivalry heats up as both chase blockbuster PsA market
September 17, 2023 | americanbankingnews.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Downgraded to "Neutral" at Bryan, Garnier & Co
September 15, 2023 | msn.com
Cantor Fitzgerald Reiterates MoonLake Immunotherapeutics - (MLTX) Overweight Recommendation
September 14, 2023 | wsj.com
MoonLake Immunotherapeutics
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 13, 2023 | msn.com
Needham Reiterates MoonLake Immunotherapeutics - (MLTX) Buy Recommendation
September 12, 2023 | finance.yahoo.com
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10%
September 12, 2023 | fool.com
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
September 12, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), InflaRx (IFRX)
September 6, 2023 | finance.yahoo.com
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
August 31, 2023 | msn.com
Needham Initiates Coverage of MoonLake Immunotherapeutics - (MLTX) with Buy Recommendation
August 28, 2023 | msn.com
Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)
August 14, 2023 | msn.com
Wedbush Reiterates MoonLake Immunotherapeutics - (MLTX) Outperform Recommendation
August 13, 2023 | fool.com
MoonLake Immunotherapeutics (NASDAQ: MLTX)
August 11, 2023 | markets.businessinsider.com
Jefferies Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
August 11, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Ligand Pharma (LGND) and Immunocore Holdings (IMCR)
August 11, 2023 | markets.businessinsider.com
MoonLake Immunotherapeutics (MLTX) Receives a Buy from LifeSci Capital
August 10, 2023 | finanznachrichten.de
MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023 | finance.yahoo.com
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 2, 2023 | msn.com
MoonLake Immunotherapeutics - (MLTX) Price Target Increased by 11.60% to 61.81
August 1, 2023 | msn.com
Wedbush Maintains MoonLake Immunotherapeutics - (MLTX) Outperform Recommendation
July 28, 2023 | markets.businessinsider.com
Wedbush Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
July 25, 2023 | finance.yahoo.com
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MLTX
CUSIP
N/A
CIK
1821586
Web
www.moonlaketx.com
Phone
41-41-510-8022
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.80
High Stock Price Forecast
$86.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+6.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-49,970,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-23.18%
Return on Assets
-22.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
70.97
Quick Ratio
70.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
42.36

Miscellaneous

Outstanding Shares
62,446,000
Free Float
52,910,000
Market Cap
$3.44 billion
Optionable
Not Optionable
Beta
1.46
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Jorge Santos da Silva (Age 45)
    Co-Founder, CEO & Director
    Comp: $1.11M
  • Dr. Kristian Reich (Age 57)
    Co-Founder & Chief Scientific Officer
    Comp: $1.2M
  • Mr. Matthias Bodenstedt (Age 35)
    Chief Financial Officer
    Comp: $588.25k
  • Mr. Oliver Daltrop
    Chief Technical Officer
  • Nicolas Mosimann
    Gen. Counsel
  • Annett Zippel
    Director of People & Culture
  • Ms. Nuala Brennan
    Chief Clinical Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MLTX Stock - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price forecast for 2023?

10 brokers have issued 1 year price objectives for MoonLake Immunotherapeutics' shares. Their MLTX share price forecasts range from $16.00 to $86.00. On average, they predict the company's share price to reach $58.80 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2023?

MoonLake Immunotherapeutics' stock was trading at $10.50 at the beginning of 2023. Since then, MLTX shares have increased by 424.5% and is now trading at $55.07.
View the best growth stocks for 2023 here.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our MLTX earnings forecast.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) posted its earnings results on Thursday, August, 10th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.04.

What ETFs hold MoonLake Immunotherapeutics' stock?

ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Harbor Health Care ETF (MEDI), First Trust IPOX Europe Equity Opportunities ETF (FPXE) and BlackRock Future Health ETF (BMED).Goldman Sachs Future Health Care Equity ETF (GDOC).

What is MoonLake Immunotherapeutics' stock symbol?

MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX."

Who are MoonLake Immunotherapeutics' major shareholders?

MoonLake Immunotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Cormorant Asset Management LP (15.45%), Citadel Advisors LLC (3.83%), Alliancebernstein L.P. (1.59%), Polar Capital Holdings Plc (1.40%), BlackRock Inc. (1.25%) and Banque Pictet & Cie SA (1.21%).
View institutional ownership trends.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MoonLake Immunotherapeutics' stock price today?

One share of MLTX stock can currently be purchased for approximately $55.07.

How much money does MoonLake Immunotherapeutics make?

MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $3.44 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How can I contact MoonLake Immunotherapeutics?

The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com.

This page (NASDAQ:MLTX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -